AT293390B - Verfahren zur Herstellung von neuen substituierten Chinazolinen oder von deren Säureadditionssalzen - Google Patents

Verfahren zur Herstellung von neuen substituierten Chinazolinen oder von deren Säureadditionssalzen

Info

Publication number
AT293390B
AT293390B AT985167A AT985167A AT293390B AT 293390 B AT293390 B AT 293390B AT 985167 A AT985167 A AT 985167A AT 985167 A AT985167 A AT 985167A AT 293390 B AT293390 B AT 293390B
Authority
AT
Austria
Prior art keywords
production
acid addition
addition salts
new substituted
substituted quinazolines
Prior art date
Application number
AT985167A
Other languages
English (en)
Original Assignee
Pfizer & Co C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer & Co C filed Critical Pfizer & Co C
Application granted granted Critical
Publication of AT293390B publication Critical patent/AT293390B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT985167A 1966-10-31 1967-10-31 Verfahren zur Herstellung von neuen substituierten Chinazolinen oder von deren Säureadditionssalzen AT293390B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59049466A 1966-10-31 1966-10-31
US19082A US3594480A (en) 1966-10-31 1970-03-12 Nitrogen heterocycles for therapeutic administration

Publications (1)

Publication Number Publication Date
AT293390B true AT293390B (de) 1971-10-11

Family

ID=26691822

Family Applications (1)

Application Number Title Priority Date Filing Date
AT985167A AT293390B (de) 1966-10-31 1967-10-31 Verfahren zur Herstellung von neuen substituierten Chinazolinen oder von deren Säureadditionssalzen

Country Status (7)

Country Link
US (1) US3594480A (de)
AT (1) AT293390B (de)
BE (1) BE705970A (de)
CH (1) CH510032A (de)
FR (3) FR8470M (de)
GB (1) GB1199768A (de)
NL (1) NL6714762A (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637701A (en) * 1969-03-03 1972-01-25 Sandoz Ag Certain nitrate derivatives of 4-aminoquinazolines
BE759842R (fr) * 1969-12-05 1971-06-03 Sandoz Sa Nouveaux derives de la 4-amino-quinazoline, leur preparation etmedicaments contenant ces
US3885035A (en) * 1972-04-05 1975-05-20 Sandoz Ag Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3857944A (en) * 1972-04-21 1974-12-31 Sandoz Ag 1-piperazinoisoquinolines as inotropic agents
CH583225A5 (de) * 1972-09-25 1976-12-31 Sandoz Ag
GB1582407A (en) * 1977-06-07 1981-01-07 Worcester Controls Uk Ltd Annular seals
US4171363A (en) * 1977-02-22 1979-10-16 Bristol-Myers Company 1,2,3-Thiadiazole process
IN148482B (de) 1977-06-03 1981-03-07 Pfizer
US4370328A (en) 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
CA1086735A (en) * 1977-11-03 1980-09-30 John C. Danilewicz Piperidino-quinazolines
CH651027A5 (de) * 1982-11-12 1985-08-30 Sandoz Ag Heterocyclische verbindungen, ihre herstellung und verwendung.
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP0669324A4 (de) * 1993-09-10 1996-04-03 Eisai Co Ltd Chinazolin derivate.
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5658902A (en) * 1994-12-22 1997-08-19 Warner-Lambert Company Quinazolines as inhibitors of endothelin converting enzyme
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
DE19756388A1 (de) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
IT1302677B1 (it) * 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
EP1466907B1 (de) * 2001-12-19 2011-08-10 Ube Industries, Ltd. Verfahren zur herstellung von chinazolin-4-on und derivaten davon
US8367824B2 (en) * 2002-01-28 2013-02-05 Ube Industries Ltd. Process for producing quinazolin-4-one derivative
GB0302882D0 (en) * 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
CN1774425A (zh) * 2003-04-16 2006-05-17 霍夫曼-拉罗奇有限公司 喹唑啉化合物
AU2004229163A1 (en) * 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag (6-(phenoxy)-pyrido`3,4-d! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS
CN115108999B (zh) * 2019-07-26 2023-11-03 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途

Also Published As

Publication number Publication date
DE1795787A1 (de) 1975-04-10
FR8470M (de) 1972-06-09
FR8482M (de) 1972-06-09
US3594480A (en) 1971-07-20
CH510032A (de) 1971-07-15
DE1695593A1 (de) 1972-03-16
GB1199768A (en) 1970-07-22
DE1795787B2 (de) 1976-06-24
FR8481M (de) 1972-06-09
NL6714762A (de) 1968-05-01
BE705970A (de) 1968-04-30
DE1695593B2 (de) 1975-12-11

Similar Documents

Publication Publication Date Title
AT293390B (de) Verfahren zur Herstellung von neuen substituierten Chinazolinen oder von deren Säureadditionssalzen
AT280997B (de) Verfahren zur herstellung von neuen amino-dihalogenphenylaethanolaminen sowie von deren saeureadditionssalzen
AT302276B (de) Verfahren zur Herstellung von neuen α-tert. Butylaminopropiophenonen und deren Säureadditionssalzen
AT284817B (de) Verfahren zur herstellung von neuen amino-monohalogenphenylaethanolaminen und deren salzen
AT300814B (de) Verfahren zur Herstellung von neuen Chinazolinverbindungen und von deren Säureadditionssalzen
AT277979B (de) Verfahren zur Herstellung von neuen Phenoxypropanolaminen und deren Säureadditionssalzen
CH471062A (de) Verfahren zur Herstellung von Sorbinsäure und deren Salzen
AT281835B (de) Verfahren zur Herstellung von neuen Sulfonamiden sowie von deren Salzen
AT254899B (de) Verfahren zur Herstellung von neuen Benzolsulfonylharnstoffen oder deren Salzen
CH476025A (de) Verfahren zur Herstellung von D-Ribose-5-Phosphorsäureestern oder deren Salzen
AT323190B (de) Verfahren zur herstellung von neuen carbamoylaminoalkylbenzolsulfonylharnstoffen und deren salzen
AT274813B (de) Verfahren zur Herstellung von neuen 4-Hydroxy-chinolinen, sowie deren Salzen
AT291220B (de) Verfahren zur Herstellung von neuen Propionamidinen oder deren Säureadditionssalzen
AT264539B (de) Verfahren zur Herstellung von Guanidinen oder deren Salzen
AT260203B (de) Verfahren zur Herstellung von neuen Dibenzocyloheptenen und deren Säureadditions salzen
AT286301B (de) Verfahren zur herstellung von neuen phenanthridinderivatensowie ihrer saeureadditionssalze
AT273942B (de) Verfahren zur Herstellung von neuen basischen Biphenyläthern und ihren Säureadditionssalzen
AT283349B (de) Verfahren zur herstellung von neuen 1-acyl-3-indolylcarbonsaeurederivaten
AT281854B (de) Verfahren zur Herstellung von neuen Amidinoharnstoffen oder ihren Säureadditionssalzen
AT268245B (de) Verfahren zur Herstellung von neuen Bisphenolschwefelsäureestersalzen
AT286264B (de) Verfahren zur herstellung von neuen 1-phenoxy-2-aminoalkanen sowie von deren saeureadditionssalzen
AT274777B (de) Verfahren zur Herstellung von neuen basischen Äthern und ihren Säureadditionssalzen
AT304569B (de) Verfahren zur Herstellung von neuen Purin-Verbindungen und deren Salzen
AT285605B (de) Verfahren zur Herstellung von neuen Benzodioxanderivaten und deren Säureadditionssalzen
AT286267B (de) Verfahren zur Herstellung von neuen Amino-dihalogenphenyläthanolaminen sowie von deren Säureadditionssalzen

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
ELJ Ceased due to non-payment of the annual fee